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Cancer: Clinical Trial Fantasy or Practice Reality?Prostate cancer (PCa) is the second most common male cancer
worldwide1 and 5th common male cancer in Taiwan. In contrast
to Western countries, the proportion of PCa patients presenting
with advanced stage at ﬁrst diagnosis is 20-40% for distant disease
in Taiwan. Radical prostatectomy and external-beam radiation is
the mainstay of localized prostate cancer, many patients subse-
quently developmetastatic disease which is no cure for this disease
stage. Since androgen stimulates androgen receptor (AR) to drive
the growth and progression of prostate cancer cells, androgen
deprivation therapy (ADT) is the standard treatment of hormone-
sensitive advanced prostate cancer.2 Despite 90% of patients will
respond to ADT, the majority of patients progress to castration-
resistant prostate cancer (CRPC) within 2-3 years.3,4 Until very
recently, chemotherapy with docetaxel was the only effective treat-
ment to show a 20-30% improvement in overall survival (OS)
beneﬁt formenwithmetastatic castration-resistant prostate cancer
on the basis of two parallel randomized clinical trials TAX 3275 and
SWOG-9916.6 Docetaxel was the ﬁrst cytotoxic drug to demon-
strate OS improvement in PCa since year 2004. Nowadays, several
active agents have been introduced in clinical practice based on
positive RCT results to show the efﬁcacy of two new androgen-
AR-axis inhibitors (abiraterone7 and enzalutamide),8 an immuno-
therapy (sipuleuce-T),9 and an a-emitter (radium-223),10 a new
microtubule-targeting chemotherapy (cabazitazel),11 all able to
prolong OS.
The underlying mechanisms contributing to CRPC could be
divided into androgen-AR-dependent and androgen-AR-
independent pathways as a consequence of genetic/epigenetic al-
terations induced by the selective pressure of ADT.12e17
Hormone-sensitive PCa should be considered a heterogeneous dis-
ease, characterized by the coexistence of both AR-positive and AR-
negative tumor cells. Castration is able to induce clonal selection
and subsequent growth of androgen-independent cellular clones.18
These observations provide a rationale to investigate whether
administering chemotherapy to patients who are sensitive to hor-
mone therapy can improve the efﬁcacy and tolerability of docetaxel
and prolong patient survival outcomes.
More recently, the GETUG-15, CHAARTED and STAMPEDE
studies all assessed the efﬁcacy and tolerability of ADT with or
without docetaxel in menwith metastatic hormone-sensitive pros-
tate cancer. 4,19,20 A systemic review and meta-analysis study has
evaluated the issue regarding addition of docetaxel to ADT for pa-
tients with hormone-sensitive metastatic prostate cancer mainly
based on the results of the aforementioned three RCTs.21 In this re-
view article, overall, 2951 patients were included in the three trials.http://dx.doi.org/10.1016/j.urols.2015.11.008
1879-5226/Copyright © 2015, Taiwan Urological Association. Published by Elsevier Ta
creativecommons.org/licenses/by-nc-nd/4.0/).Two trials enrolled only metastatic patients; in the third trial, 61%
were metastatic. A total of 2262 patients (951 docetaxel and ADT;
1311 ADT alone) were metastatic. Most patients had a good perfor-
mance status. In metastatic patients, the addition of docetaxel was
associated with improved OS (hazard ratio [HR]: 0.73; 95% conﬁ-
dence interval [CI], 0.60-0.90; p ¼ 0.002), with non-signiﬁcant het-
erogeneity among the three trials. Considering the whole study
population (2951 patients), the addition of docetaxel was associ-
ated with a similar OS improvement (HR: 0.74; 95% CI, 0.61-0.91;
p ¼ 0.003). Although with limited statistical power, no signiﬁcant
interaction was demonstrated between the addition of docetaxel
and the high or low volume of disease (p ¼ 0.5). The addition of
docetaxel was associated with improvement in progression-free
survival (metastatic patients: HR: 0.63; 95% CI, 0.57-0.70;
p < 0.001). This meta-analysis shows a signiﬁcant OS beneﬁt
from concomitant administration of docetaxel and ADT in patients
with metastatic hormone-sensitive PCa.
A quantitative synthesis of the evidence currently available
about the treatment strategy by adding docetaxel to ADT for pa-
tients with hormone-sensitive metastatic prostate cancer can be
really helpful for clinical decisions because these three phase 3 tri-
als (GETUG-15, CHAARTED-E3805 and STAMPEDE) demonstrated
the improvement of OS by the activity of docetaxel in combination
with endocrine therapy. Administering chemotherapy tometastatic
PCa patients in an early phase of the disease has several potential
advantages. Patients with metastatic hormone-sensitive disease
are, on average, in better performance status compared with
CRPC setting, due to a lower burden of disease. They are more
eligible for chemotherapy with better tolerance and adequate
drug dose intensity. Subgroup data from GETUG-15 and
CHAARTED-E3805 trials have suggested that concomitant adminis-
tration of docetaxel with ADT achieved more survival beneﬁt in pa-
tients with high-volume disease. In patients with hormone-
sensitive disease, the presence of extensive disease (visceral metas-
tases or appendicular skeletal involvement) is related to a worse
prognosis.22e24 In both the GETUG-15 and CHAARTED-E3805 trials,
high-volume disease was deﬁned as the presence of visceral metas-
tases or the presence of at least four bone lesions, with one or more
lesions in any bone beyond the spine/pelvis. For patients with
lower-volume disease, a longer follow-up with a higher number
of events, together with the availability of this subgroup analysis
also in the STAMPEDE trial, could increase the statistical power to
evaluate the survival beneﬁt derived from adding docetaxel to ADT.
In addition to disease burden, the discrepancy of survival beneﬁt
between GETUG-15 and CHAARTED-E3805 could be the availabilityiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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during trial accrual times. 30% of combination treatment group and
17% of ADT alone group received subsequent cabazitaxel treatment
after initial treatment failure in CHAARTED-E3805 compared with
only 3% (combination treatment group) and 2% (ADT alone) of pa-
tients with treatment failure receiving cabazitaxel treatment in
GETUG-15. In CHAARTED-E3805 study, 63% of combination treat-
ment group and 45% of ADTalone group received either abiraterone
or enzalutamide after initial treatment failure. However, only 20%
patients in both arms received abiraterone or enzalutamide treat-
ment after initial treatment failure in GETUG-15 study.
The drug-related toxicity should be concerned especially for pa-
tients received combination treatment with docetaxel and ADT.
Treatment-related death was four from combination group in
GETUG-15 and one from combination group in CHAARTED-E3805,
respectively, compared with no treatment-related deaths with
ADT alone. In addition, chemotherapy toxicity is often worse in
the real-world population compared with the toxicity reported in
clinical trials. A careful selection of patients to be treated with
upfront docetaxel is essential for a favorable beneﬁt-risk ratio.
The discovery of new therapies and reﬁnement of existing ones
continue to improve outcomes in men with mHSPC. The ﬁrst-line
chemo-hormonal therapy with docetaxel and ADT improving sur-
vival in men with high-volume mHSPC could serve as a major
breakthrough in the management of advanced prostate cancer.
The beneﬁt from this upfront approach for low-volume mHSPC re-
mains to be seen in a long-term follow-up. However, due to the po-
tential lethal toxicity of cytotoxic chemotherapy, identiﬁcation of
suitable candidates for the ﬁrst-line chemo-hormonal therapy is
warranted. Therefore, risk stratiﬁcation and the development of
novel biomarkers for this upfront approach will create not only
clinical trial fantasy but also turn out to be clinical practice reality.
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